# Semaglutide in Nonalcoholic Fatty Liver Disease

Study · id `cardio:ct-nct05813249` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05813249](<https://clinicaltrials.gov/study/NCT05813249>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05813249

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.

## Technical summary

Registry record NCT05813249. Non-randomized; no masking; primary purpose treatment. Start 2023-02-15 (actual); primary completion 2024-02-15 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 180 participants (enrolled count; ClinicalTrials.gov record NCT05813249, source copy `cardio:ctgov-nct05813249-2024-04-02`, retrieved 2026-10-26)
- Started: 2023-02-15 (actual) (ClinicalTrials.gov record NCT05813249, source copy `cardio:ctgov-nct05813249-2024-04-02`, retrieved 2026-10-26)
- Primary completion: 2024-02-15 (actual) (ClinicalTrials.gov record NCT05813249, source copy `cardio:ctgov-nct05813249-2024-04-02`, retrieved 2026-10-26)
- Completion: 2024-04-01 (actual) (ClinicalTrials.gov record NCT05813249, source copy `cardio:ctgov-nct05813249-2024-04-02`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT05813249, source copy `cardio:ctgov-nct05813249-2024-04-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05813249-2024-04-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Semaglutide in Nonalcoholic Fatty Liver Disease
- Condition: Non-alcoholic Fatty Liver Disease
- Intervention (Drug): Rybelsus Oral Product
- Intervention (Drug): Ozempic Injectable Product
- Intervention (Drug): Tocopherol and/or Actos
- Lead sponsor: Zagazig University
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 2e78caf122c05b9b01de56b7369b720bad0dad8ba209687572c6aa8bf00d4f00
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
